Detection of Novel Urine Markers Using Immune Complexome Analysis in Bladder Cancer Patients: A Preliminary Study

Aibara, Nozomi; Miyata, Yasuyoshi; Araki, Kyohei; Sagara, Yuji; Mitsunari, Kensuke; Matsuo, Tomohiro; Ohba, Kenkichi; Mochizuki, Yoshinari; Sakai, Hideki; Ohyama, Kaname

doi:10.21873/invivo.12476

Cited by 4 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the diagnosis test cohort, a novel biomarker panel including 13 proteins has 90.9% sensitivity and 73.3% specificity, which outperformed the results of biomarkers based on urinary proteomics in the previous study . Six proteins including MMP10, HBB, APOA1, SAA4, A2M, and FGG of 13 biomarkers highlighted as markers for the primary diagnosis of BCa have been previously reported. Three proteins including GTPBP1, MIF, and F13A1 have been reported in BCa-related genomics studies.…”

Section: Discussionmentioning

confidence: 63%

Comprehensive Urinary Proteome Profiling Analysis Identifies Diagnosis and Relapse Surveillance Biomarkers for Bladder Cancer

Chang,

Chen,

Yin

et al. 2024

J. Proteome Res.

View full text Add to dashboard Cite

Bladder cancer (BCa) is the predominant malignancy of the urinary system. Herein, a comprehensive urine proteomic feature was initially established for the noninvasive diagnosis and recurrence monitoring of bladder cancer. 279 cases (63 primary BCa, 87 nontumor controls (NT), 73 relapsed BCa (BCR), and 56 nonrelapsed BCa (BCNR)) were collected to screen urinary protein biomarkers. 4761 and 3668 proteins were qualified and quantified by DDA and sequential window acquisition of all theoretical mass spectra (SWATH-MS) analysis in two discovery sets, respectively. Upregulated proteins were validated by multiple reaction monitoring (MRM) in two independent combined sets. Using the multi-support vector machine-recursive feature elimination (mSVM-RFE) algorithm, a model comprising 13 proteins exhibited good performance between BCa and NT with an AUC of 0.821 (95% CI: 0.675−0.967), 90.9% sensitivity (95% CI: 72.7−100%), and 73.3% specificity (95% CI: 53.3− 93.3%) in the diagnosis test set. Meanwhile, an 11-marker classifier significantly distinguished BCR from BCNR with 75.0% sensitivity (95% CI: 50.0−100%), 81.8% specificity (95% CI: 54.5−100%), and an AUC of 0.784 (95% CI: 0.609−0.959) in the test cohort for relapse surveillance. Notably, six proteins (SPR, AK1, CD2AP, ADGRF1, GMPS, and C8A) of 24 markers were newly reported. This paper reveals novel urinary protein biomarkers for BCa and offers new theoretical insights into the pathogenesis of bladder cancer (data identifier PXD044896).

show abstract

Section: Discussionmentioning

confidence: 63%

Comprehensive Urinary Proteome Profiling Analysis Identifies Diagnosis and Relapse Surveillance Biomarkers for Bladder Cancer

Chang,

Chen,

Yin

et al. 2024

J. Proteome Res.

View full text Add to dashboard Cite

show abstract

“…Early diagnosis can significantly improve the treatment effect and cure rate [ 2 ]. Therefore, it is very important to find tumor markers for bladder urothelial carcinoma, because early detection of tumors can reduce the economic burden [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Expression and prognostic value of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma

Xiang

Chen

et al. 2022

BMC Urol

View full text Add to dashboard Cite

Objective To investigate the expression intensity of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma and its predictive value for the recurrence after transurethral resection of bladder tumor. Methods A retrospective analysis was made of 194 specimens who underwent transurethral resection of bladder tumors in our hospital from January 2014 to January 2016 and completed follow-up. The expression intensity of CA-IX and the clinical data of the patients were analyzed, and the subjects were divided into positive group and negative group according to the expression intensity of CA-IX. The age, gender, T stage, degree of differentiation, tumor number, tumor diameter, recurrence of each group was analyzed. Logistic univariate and multivariate analysis was used successively to find independent influencing factors for predicting the recurrence of bladder urothelial carcinoma after resection. The Kaplan–Meier survival curve was drawn according to the relationship between CA-IX expression intensity and postoperative recurrence. Results The positive expression rates of CA-IX in bladder urothelial carcinomas were 68.1% (132/194). The positive expression of CA-IX had no statistical significance with age, gender and tumor diameter (P > 0.05), while the positive expression of CA-IX had statistical significance with tumor T stage, tumor differentiation, tumor number and recurrence (P < 0.05); Logistic regression analysis showed that clinical T stage, tumor differentiation, tumor number, and CA-IX expression intensities were independent risk factors for predicting recurrence of bladder urothelial carcinoma after resection (P < 0.05); There were 59 cases of recurrence in the positive expression of CA-IX group, with a recurrence rate of 44.69% (59/132), and 17 cases of recurrence in the negative expression group, with a recurrence rate of 27.41% (17/62). The mean recurrence time of CA-IX positive group was 29.93 ± 9.86 (months), and the mean recurrence time of CA-IX negative group was 34.02 ± 12.44 (months). The Kaplan–Meier survival curve showed that the recurrence rate and recurrence time of patients with positive expression of CA-IX in bladder urothelial carcinomas were significantly higher than those of patients with negative expression of CA-IX. Conclusion CA-IX is highly expressed in bladder urothelial carcinoma, is a good tumor marker, and can be used as a good indicator for predicting the recurrence of bladder urothelial carcinoma after transurethral resection of bladder tumor.

show abstract

“…Early diagnosis can signi cantly improve the treatment effect and cure rate [2] . Therefore, it is very important to nd tumor markers for bladder urothelial carcinoma, because early detection of tumors can reduce the economic burden [3] .…”

Section: Introductionmentioning

confidence: 99%

Expression and prognostic value of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma

Xiang

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective: To investigate the expression intensity of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma and its predictive value for the recurrence after transurethral resection of bladder tumor. Methods: A retrospective analysis was made of 194 specimens who underwent transurethral resection of bladder tumors in our hospital from January 2014 to January 2016 and completed follow-up. The expression intensity of CA-IX and the clinical data of the patients were analyzed, and the subjects were divided into positive group and negative group according to the expression intensity of CA-IX. The age, gender, T stage, degree of differentiation, tumor number, tumor diameter, recurrence of each group was analyzed. Logistic univariate and multivariate analysis was used successively to find independent influencing factors for predicting the recurrence of bladder urothelial carcinoma after resection. The Kaplan-Meier survival curve was drawn according to the relationship between CA-IX expression intensity and postoperative recurrence. Results: The positive expression rates of CA-IX in bladder urothelial carcinomas were 68.1% (132/194). The positive expression of CA-IX had no statistical significance with age, gender and tumor diameter (P>0.05), while the positive expression of CA-IX had statistical significancewith tumor T stage, tumor differentiation, tumor number and recurrence (P<0.05); Logistic regression analysis showed that clinical T stage, tumor differentiation, tumor number, and CA-IX expression intensities were independent risk factors for predicting recurrence of bladder urothelial carcinoma after resection (P<0.05); There were 59 cases of recurrence in the positive expression of CA-IX group, with a recurrence rate of 44.69% (59/132), and 17 cases of recurrence in the negative expression group, with a recurrence rate of 27.41% (17/62). The mean recurrence time of CA-IX positive group was 29.93±9.86 (months), and the mean recurrence time of CA-IX negative group was 34.02±12.44 (months). The Kaplan-Meier survival curve showed that the recurrence rate and recurrence time of patients with positive expression of CA-IX in bladder urothelial carcinomas were significantly higher than those of patients with negative expression of CA-IX. Conclusion: CA-IX is highly expressed in bladder urothelial carcinoma, is a good tumor marker, and can be used as a good indicator for predicting the recurrence of bladder urothelial carcinoma after transurethral resection of bladder tumor.

show abstract

Detection of Novel Urine Markers Using Immune Complexome Analysis in Bladder Cancer Patients: A Preliminary Study

Cited by 4 publications

References 45 publications

Comprehensive Urinary Proteome Profiling Analysis Identifies Diagnosis and Relapse Surveillance Biomarkers for Bladder Cancer

Comprehensive Urinary Proteome Profiling Analysis Identifies Diagnosis and Relapse Surveillance Biomarkers for Bladder Cancer

Expression and prognostic value of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma

Expression and prognostic value of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma

Contact Info

Product

Resources

About